• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine

    Gabrielle Lakusta
    Mar. 06, 2018 09:26AM PST
    Pharmaceutical Investing

    Bavarian Nordic (OMX: BAVA) today announced additional positive data from its 421 patient, Phase 2 study investigating the safety and immune effects of its universal RSV vaccine, MVA-BN RSV in an older adult population. As quoted in the press release: “The presence of mucosal IgA in vaccinated subjects is a truly encouraging, demonstrating that our …

    Bavarian Nordic (OMX: BAVA) today announced additional positive data from its 421 patient, Phase 2 study investigating the safety and immune effects of its universal RSV vaccine, MVA-BN RSV in an older adult population.

    As quoted in the press release:

    “The presence of mucosal IgA in vaccinated subjects is a truly encouraging, demonstrating that our vaccine is performing as intended. The ability to fight off a severe RSV infection wanes as individuals get older. Observing a booster effect in this elderly population gives us additional confidence that protection against RSV may be possible in this at-risk population using our vaccine. With a mortality rate on par with influenza, the need for an RSV vaccine remains significant,” said Paul Chaplin, President and CEO of Bavarian Nordic.

    Click here to read the full press release.

    pharmaceutical investingphase 2 study
    The Conversation (0)

    Go Deeper

    AI Powered
    Pfizer Reports First-Quarter 2023 Results

    Pfizer Reports First-Quarter 2023 Results

    Biotech Outlook: World Edition

    Biotech Outlook: World Edition

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×